Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant

Allogeneic hematopoietic cell transplantation (alloHCT) is a potentially curative treatment for myelodysplastic syndromes (MDS), but patients who relapse after transplant have poor outcomes. In order to understand the contribution of tumor clonal evolution to disease progression,we applied exome and...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JCI Insight
Main Authors: Jacoby, Meagan A., Duncavage, Eric J., Chang, Gue Su, Miller, Christopher A., Shao, Jin, Elliott, Kevin, Robinson, Joshua, Fulton, Robert S., Fronick, Catrina C., O’Laughlin, Michelle, Heath, Sharon E., Pusic, Iskra, Welch, John S., Link, Daniel C., DiPersio, John F., Westervelt, Peter, Ley, Timothy J., Graubert, Timothy A., Walter, Matthew J.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Clinical Investigation 2018
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5922277/
https://ncbi.nlm.nih.gov/pubmed/29515031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.98962
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares